|
1
|
Shirakawa Y, Naomoto Y, Kimura M, et al:
Topological analysis of p21WAF1/CIP1 expression in esophageal
squamous dysplasia. Clin Cancer Res. 6:541–550. 2000.PubMed/NCBI
|
|
2
|
Natsugoe S, Xiangming C, Matsumoto M, et
al: Smad4 and transforming growth factor β1 expression in patients
with squamous cell carcinoma of the esophagus. Clin Cancer Res.
8:1838–1842. 2002.PubMed/NCBI
|
|
3
|
Friess H, Yamanaka Y, Büchler M, et al:
Enhanced expression of transforming growth factor beta isoforms in
pancreatic cancer correlates with decreased survival.
Gastroenterology. 105:1846–1856. 1993.PubMed/NCBI
|
|
4
|
Fukai Y, Fukuchi M, Masuda N, et al:
Reduced expression of transforming growth factor-beta receptors is
an unfavorable prognostic factor in human esophageal squamous cell
carcinoma. Int J Cancer. 104:161–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fukuchi M, Masuda N, Miyazaki T, et al:
Decreased Smad4 expression in the transforming growth factor-beta
signaling pathway during progression of esophageal squamous cell
carcinoma. Cancer. 95:737–743. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang LH, Kim SH, Lee JH, et al:
Inactivation of SMAD4 tumor suppressor gene during gastric
carcinoma progression. Clin Cancer Res. 13:102–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lv J, Cao XF, Ji L, et al: Association of
β-catenin, Wnt1, Smad4, Hoxa9 and Bmi-1 with the prognosis of
esophageal squamous cell carcinoma. Med Oncol. 29:151–160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patiño-García A, Sotillo-Piñeiro E and
Sierrasesúmaga-Ariznabarreta L: p21WAF1 mutation is not a
predominant alteration in pediatric bone tumors. Pediatr Res.
43:393–395. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nadal A, Jares P, Cazorla M, et al:
p21WAF1/Cip1 expression is associated with cell differentiation but
not with p53 mutations in squamous cell carcinomas of the larynx. J
Pathol. 183:156–163. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seta T, Imazeki F, Yokosuka O, et al:
Expression of p53 and p21WAF1/CIP1 proteins in gastric and
esophageal cancers: comparison with mutations of the p53 gene. Dig
Dis Sci. 43:279–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shiozaki A, Nakashima S, Ichikawa D, et
al: Prognostic significance of p21 expression in patients with
esophageal squamous cell carcinoma. Anticancer Res. 33:4329–4335.
2013.PubMed/NCBI
|
|
12
|
Yang G, Zhang Z, Liao J, et al:
Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human
esophageal carcinomas and neighboring epithelia from a high-risk
area in northern China. Int J Cancer. 72:746–751. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohashi K, Nemoto T, Eishi Y, et al:
Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in
oesophageal squamous cell carcinomas. Virchows Arch. 430:389–395.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia del Muro X, Condom E, Vigues F, et
al: p53 and p21 expression levels predict organ preservation and
survival in invasive bladder carcinoma treated with a
combined-modality approach. Cancer. 100:1859–1867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rose SL, Goodheart MJ, DeYoung BR, Smith
BJ and Buller RE: p21 expression predicts outcome in p53-null
ovarian carcinoma. Clin Cancer Res. 9:1028–1032. 2003.PubMed/NCBI
|
|
16
|
Caffo O, Doglioni C, Veronese S, et al:
Prognostic value of p21(WAF1) and p53 expression in breast
carcinoma: an immunohistochemical study in 261 patients with
long-term follow-up. Clin Cancer Res. 2:1591–1599. 1996.PubMed/NCBI
|
|
17
|
Lam KY, Law S, Tin L, Tung PH and Wong J:
The clinicopathological significance of p21 and p53 expression in
esophageal squamous cell carcinoma: an analysis of 153 patients. Am
J Gastroenterol. 94:2060–2068. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sarbia M, Stahl M, zur Hausen A, et al:
Expression of p21WAF1 predicts outcome of esophageal cancer
patients treated by surgery alone or by combined therapy
modalities. Clin Cancer Res. 4:2615–2623. 1998.PubMed/NCBI
|
|
19
|
Erber R, Klein W, Andl T, et al: Aberrant
p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J
Cancer. 74:383–389. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gabbert HE, Nakamura Y, Shimoda T, Field
JK, Hainaut P and Inoue H: Squamous cell carcinoma of the
oesophagusWorld Health Organization Classification of Tumours
Pathology and Genetics of Tumours of the Digestive System. Hamilton
SR and Aaltonen LA: IARCPress; Lyon, France: pp. 16–32. 2000
|
|
21
|
Korchynskyi O, Landström M, Stoika R, et
al: Expression of Smad proteins in human colorectal cancer. Int J
Cancer. 82:197–202. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiangming C, Natsugoe S, Takao S, Hokita
S, Ishigami S, et al: Preserved Smad4 expression in the
transforming growth factor beta signaling pathway is a favorable
prognostic factor in patients with advanced gastric cancer. Clin
Cancer Res. 7:277–282. 2001.PubMed/NCBI
|
|
23
|
Miyaki M, Iijima T, Konishi M, et al:
Higher frequency of Smad4 gene mutation in human colorectal cancer
with distant metastasis. Oncogene. 18:3098–3103. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seoane J: p21(WAF1/CIP1) at the switch
between the anti-oncogenic and oncogenic faces of TGFbeta. Cancer
Biol Ther. 3:226–227. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heldin CH, Miyazono K and ten Dijke P:
TGF-beta signalling from cell membrane to nucleus through SMAD
proteins. Nature. 390:465–471. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lagna G, Hata A, Hemmati-Brivanlou A and
Massagué J: Partnership between DPC4 and SMAD proteins in TGF-beta
signalling pathways. Nature. 383:832–836. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hahn SA, Schutte M, Hoque AT, et al: DPC4,
a candidate tumor suppressor gene at human chromosome 18q21.1.
Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schutte M, Hruban RH, Hedrick L, et al:
DPC4 gene in various tumor types. Cancer Res. 56:2527–2530.
1996.PubMed/NCBI
|
|
29
|
Wang J, Sun L, Myeroff L, et al:
Demonstration that mutation of the type II transforming growth
factor beta receptor inactivates its tumor suppressor activity in
replication error-positive colon carcinoma cells. J Biol Chem.
270:22044–22049. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Osawa H, Shitara Y, Shoji H, et al:
Mutation analysis of transforming growth factor beta type II
receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell
carcinoma. Int J Oncol. 17:723–728. 2000.PubMed/NCBI
|
|
31
|
Bierie B and Moses HL: TGF-beta and
cancer. Cytokine Growth Factor Rev. 17:29–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elliott RL and Blobe GC: Role of
transforming growth factor Beta in human cancer. J Clin Oncol.
23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bullock R, Maxwell WL, Graham DI, Teasdale
GM and Adams JH: Glial swelling following human cerebral contusion:
an ultrastructural study. J Neurol Neurosurg Psychiatry.
54:427–434. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Violette F and Senelar R: Pulmonary
vascular lesions caused by explosive decompression in the dog. J
Physiol (Paris). 50:556–557. 1958.(In French). PubMed/NCBI
|
|
35
|
el-Deiry WS, Tokino T, Waldman T, et al:
Topological control of p21WAF1/CIP1 expression in normal and
neoplastic tissues. Cancer Res. 55:2910–2919. 1995.PubMed/NCBI
|
|
36
|
Bachman KE, Blair BG, Brenner K, et al:
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human
epithelial cells. Cancer Biol Ther. 3:221–225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Omar EA, Behlouli H, Chevalier S and
Aprikian AG: Relationship of p21(WAF-I) protein expression with
prognosis in advanced prostate cancer treated by androgen ablation.
Prostate. 49:191–199. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zlotta AR, Noel JC, Fayt I, et al:
Correlation and prognostic significance of p53, p21WAF1/CIP1 and
Ki-67 expression in patients with superficial bladder tumors
treated with bacillus Calmette-Guerin intravesical therapy. J Urol.
161:792–798. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noda H, Maehara Y, Irie K, Kakeji Y,
Yonemura T and Sugimachi K: Growth pattern and expressions of cell
cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric
carcinoma. Cancer. 92:1828–1835. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang M, Shao ZM, Wu J, et al:
p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as
related to prognosis. Int J Cancer. 74:529–534. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Komiya T, Hosono Y, Hirashima T, et al:
p21 expression as a predictor for favorable prognosis in squamous
cell carcinoma of the lung. Clin Cancer Res. 3:1831–1835.
1997.PubMed/NCBI
|
|
42
|
Jeannon JP, Soames J, Lunec J, Awwad S,
Ashton V and Wilson JA: Expression of cyclin-dependent kinase
inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal
cancer. Clin Otolaryngol Allied Sci. 25:23–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
